Vanguard Group Inc Glycomimetics Inc Call Options Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GLYC
# of Institutions
36Shares Held
17.8MCall Options Held
0Put Options Held
0-
Bvf Inc San Francisco, CA9.54MShares$2.29 Million0.05% of portfolio
-
Siren, L.L.C. New York, NY1.97MShares$471,6270.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny781KShares$187,4640.0% of portfolio
-
Black Rock Inc. New York, NY723KShares$173,5640.0% of portfolio
-
Geode Capital Management, LLC Boston, MA521KShares$125,0930.0% of portfolio
About GLYCOMIMETICS INC
- Ticker GLYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,423,900
- Market Cap $12.6M
- Description
- GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...